Physician profile
Jesse Davis
NPI 1326689860
$662.44
in general payments reported to CMS, 2019-2025
14 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.80 · 2022: $94.17 · 2023: $48.32 · 2024: $228 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $94.17 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $90.80 | 2021 | |
| Medical Device Business Services, INC. | $90.02 | 2025 | Stratafix |
| Mallinckrodt Hospital Products INC. | $66.97 | 2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $59.00 | 2024 | Zerbaxa, Dificid, Recarbrio |
| Nuwellis, INC. | $46.40 | 2024 | Aquadex Smartflow Console |
| Kerecis Limited | $43.59 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Bioventus LLC | $34.85 | 2025 | Exogen Ultrasound Bone Healing System |
| Dilon Technologies, INC. | $32.54 | 2025 | Hemoblast Bellows |
| Novartis Pharmaceuticals Corporation | $26.11 | 2024 | |
| Daxor Corporation | $24.59 | 2023-2024 | Bva-100 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.08 | 2023 | Xifaxan |
| Myriad Genetic Laboratories, INC. | $17.20 | 2023 | Prolaris |
| Abbvie INC. | $16.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.